Reltecimod, a CD 28 T-lymphocyte receptor mimetic, inhibits T-cell stimulation by an array of bacterial pathogens.
CAT No: R2024
CAS No:1447799-33-8
Synonyms/Alias:Reltecimod;1447799-33-8;Reltecimod [INN];Reltecimod [USAN];AB103;U00J02UY29;(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(1R)-1-carboxyethyl]amino]-4-oxobutanoic acid;(5S,8S,11S,14S,17S,20S,23R)-5-((S)-1-((S)-2-((R)-2-Aminopropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-20-(carboxymethyl)-17-(4-hydroxybenzyl)-8-isobutyl-11-isopropyl-14,23-dimethyl-6,9,12,15,18,21-hexaoxo-2-thia-7,10,13,16,19,22-hexaazatetracosan-24-oic acid;Reltecimod [WHO-DD];Reltecimod (USAN/INN);Reltecimod [USAN:INN];UNII-U00J02UY29;CHEMBL3989950;EX-A9769;HY-P1698;AKOS040747616;DA-67150;CS-0090321;D11281;Q27290502;D-ALANYL(HUMAN T-CELL-SPECIFIC SURFACE GLYCOPROTEIN CD28-(8-15)-PEPTIDYL)-D-ALANINE;D-ALANINE, D-ALANYL-L-SERYL-L-PROLYL-L-METHIONYL-L-LEUCYL-L-VALYL-L-ALANYL-L-TYROSYL-L-.ALPHA.-ASPARTYL-;D-Alanine, D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-alpha-aspartyl-;D-ALANYL-(T-CELL-SPECIFIC SURFACE GLYCOPROTEIN CD28-(8-15)- PEPTIDE)-D-ALANINE:D-ALANYL-L-SERYL-L-PROLYL-L-METHIONYL-L-LEUCYL-L-VALYL-L-ALANYL-L-TYROSYL-L-.ALPHA.-ASPARTYL-D-ALANINE IMMUNOMODULATOR;D-Alanyl-(t-cell-specific surface glycoprotein CD28-(8-15)- peptide)-D-alanine:D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-alpha-aspartyl-D-alanine immunomodulator;D-ALANYL-L-SERYL-L-PROLYL-L-METHIONYL-L-LEUCYL-L-VALYL-L-ALANYL-L-TYROSYL-L-ASPARTYL-D-ALANINE;
Chemical Name:(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(1R)-1-carboxyethyl]amino]-4-oxobutanoic acid
Reltecimod is a synthetic peptide compound designed to mimic a conserved region of human CD28, functioning as an immunomodulatory agent in biochemical and immunological research. As a short, rationally engineered peptide, it interacts selectively with immune cell receptors, enabling precise modulation of innate and adaptive immune responses in vitro and in preclinical models. Its unique structure and mechanism of action have made it a valuable tool for dissecting cell signaling pathways, studying host-pathogen interactions, and exploring the molecular basis of immune regulation. Reltecimod's well-characterized biochemical properties and reproducible effects have positioned it as a sought-after reagent for academic, industrial, and pharmaceutical research settings focused on immunology and inflammation.
Immunological pathway analysis: Reltecimod serves as a robust probe for investigating T-cell co-stimulatory signaling and the downstream effects of CD28 pathway engagement. By mimicking the CD28 dodecapeptide region, it enables researchers to dissect the molecular events following receptor-ligand interaction, including cytokine production, cell surface marker expression, and activation of transcription factors. Such studies are critical for unraveling the complexities of immune cell activation and tolerance, providing mechanistic insights that inform the development of novel immunotherapies and vaccine adjuvants.
Host-pathogen interaction studies: The peptide's ability to modulate immune responses makes it particularly useful in experimental models of infection and inflammation. Researchers employ reltecimod to simulate or inhibit specific immune pathways during exposure to bacterial, viral, or fungal components. This approach helps elucidate the roles of innate and adaptive immunity in pathogen clearance, immunopathology, and the regulation of inflammatory cascades, thereby advancing understanding of host defense mechanisms and immune evasion strategies.
Biochemical assay development: Due to its defined peptide sequence and reproducible biological activity, reltecimod is frequently incorporated into in vitro assays designed to monitor immune cell function, receptor binding, and signal transduction. Its use in cell-based and cell-free systems allows for the quantification of immune modulatory effects, screening of potential antagonists or agonists, and validation of novel assay platforms. The peptide's stability and solubility characteristics further facilitate its integration into high-throughput screening and mechanistic studies.
Peptide-based drug discovery research: As a representative of rationally designed immunomodulatory peptides, reltecimod provides a template for the development and optimization of next-generation peptide therapeutics targeting immune checkpoints. Medicinal chemists and structural biologists utilize it as a scaffold for structure-activity relationship studies, affinity maturation, and the design of analogs with improved pharmacological properties. Its application in early-stage discovery workflows accelerates the identification of candidate molecules with potential for further preclinical investigation.
Inflammation and cytokine modulation studies: The capacity of reltecimod to influence cytokine release and immune cell recruitment is leveraged in research focused on the molecular underpinnings of acute and chronic inflammatory processes. By applying the peptide to primary cell cultures or ex vivo tissue models, investigators can monitor alterations in cytokine profiles, leukocyte activation states, and signaling network dynamics. These experiments are instrumental in mapping the contributions of specific pathways to inflammatory diseases, supporting the rational design of targeted interventions for immune-mediated disorders.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More